The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1752
In Brief: Ranitidine Returns
PDF:   US English
Disclosures
Principal Faculty
  • Jean-Marie Pflomm, Pharm.D., Editor in Chief has disclosed no relevant financial relationships.
Additional Contributor(s)
  • Amy Faucard, MLS, Associate Editor has disclosed no relevant financial relationships.
Objective(s)
Upon completion of this activity, the participant will be able to:
  1. Discuss the return of ranitidine tablets to the US market.
 Select a term to see related articles  Axid   cimetidine   famotidine   nizatidine   Pepcid   ranitidine   Tagamet   Zantac 
Med Lett Drugs Ther. 2026 Apr 13; 68(1752):63-4   doi:10.58347/tml.2026.1752e

The FDA has approved a new tablet formulation of the H2-receptor antagonist (H2RA) ranitidine from one manufacturer (VKT Pharma/Rising Pharma). It is only available by prescription. In 2020, the FDA requested that all formulations of ranitidine be withdrawn from the market because unacceptable levels of the nitrosamine compound N-nitrosodimethylamine (NDMA), a potentially carcinogenic contaminant, had been detected in ranitidine samples.

Table 1. Storage and Handling of Ranitidine Tablets
Dispense and keep tablets in the original bottle with the
desiccant.
If more than one bottle is dispensed, open only one
bottle at a time. Store additional bottles without opening
until needed for dosing.
At the time of dosing, remove one tablet from the bottle.
Immediately close the bottle, secure the cap, and keep
the bottle tightly closed to protect from moisture.
Discard unused tablets 3 months (90 days) after first
opening the bottle or by the expiration date on the bottle,
whichever is sooner.

NDMA — NDMA can be found in drinking water (as a byproduct of water disinfection) and in some processed foods. It has been found in many drugs, including nizatidine, which is structurally related to ranitidine. High levels of NDMA have been shown to induce tumors in multiple organs in animals; it is classified as a probable human carcinogen.

FDA testing found that NDMA levels in the original ranitidine formulations increased over time and when the drug was stored at high temperatures. Approval of the reformulated tablets was based on changes in the manufacturing process that improve the stability of the drug, minimizing formation of NDMA during its shelf life.

AVAILABILITY — Prior to removal, ranitidine was available over the counter (OTC) and by prescription (Zantac, and generics).1 The active ingredient in OTC Zantac 360 is now the H2RA famotidine (see Table 2).

The new formulation is available by prescription in bottles of 30 tablets containing either 150 mg or 300 mg of ranitidine. The bottles should be stored at 15-30°C (59-86°F) in a dry place and protected from light. The updated label states that the tablets must be dispensed in the original container. The label also includes storage and handling instructions for patients (see Table 1).

Table 2. H2-Receptor Antagonists
Drug
Oral Formulations
Usual Adult Dosage
Cost1
Cimetidine – generic
Tagamet HB (OTC)2 (Medtech)
200, 300, 400, 800 mg tabs;
300 mg/5 mL soln
200 mg tabs
200-400 mg bid
$18.10
18.00
Famotidine – generic
Pepcid AC (OTC)2 (J&J Consumer)
Zantac 360 (OTC)2 (Chattem)
20, 40 mg tabs; 40 mg/5 mL susp
10, 20 mg tabs
20 mg tabs
20-40 mg bid
3.20
18.203
12.503
Nizatidine – generic
150, 300 mg caps; 15 mg/mL soln
150 mg bid
50.00
Ranitidine – generic
(VKT Pharma/Rising Pharma)
150, 300 mg tabs
150 mg bid
398.10
OTC = over the counter; soln = solution; susp = suspension
1. Approximate WAC for 30 days’ treatment with the lowest usual adult dosage. WAC = wholesaler acquisition cost or manufacturer’s published
price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source:
AnalySource® Monthly. March 5, 2026. Reprinted with permission by First Databank, Inc. All rights reserved. ©2026. www.fdbhealth.com/
drug-pricing-policy.
2. Also available generically.
3. Approximate WAC for fifty 20-mg tablets.

FDA GUIDANCE — The FDA recently issued guidance on acceptable intake (AI) limits for NDMA and some other nitrosamine impurities in drugs. The AI represents the level at or below which the impurity would not be considered a safety concern.2 The updated ranitidine label states that the formulation meets FDA-approved specifications for nitrosamine impurities.

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article
arrow to next article